Table 2.
Primary and secondary outcomes
| Outcomes | Sanfu herbal patch (n = ) | Placebo (n = ) | SHP vs placebo Difference (95% CI) |
p-value |
|---|---|---|---|---|
| FEV1, L | ||||
| 1stTS | ||||
| 2ndTS | ||||
| 3rdTS | ||||
| 12 weeks follow-up | ||||
| 24 weeks follow-up | ||||
| AQLQ | ||||
| 2ndTS | ||||
| 3rdTS | ||||
| 12 weeks follow-up | ||||
| 24 weeks follow-up | ||||
| ACT | ||||
| 2ndTS | ||||
| 3rdTS | ||||
| 12 weeks follow-up | ||||
| 24 weeks follow-up | ||||
| IL-5, pg/ml | ||||
| 2ndTS | ||||
| 3rdTS | ||||
| IL-13, pg/ml | ||||
| 2ndTS | ||||
| 3rdTS | ||||
| IL-23, pg/ml | ||||
| 2ndTS | ||||
| 3rdTS | ||||
| IL-25, pg/ml | ||||
| 2ndTS | ||||
| 3rdTS | ||||
| Metallothionein-2, ng/ml | ||||
| 2ndTS | ||||
| 3rdTS | ||||
| Transgelin-2, ng/ml | ||||
| 2ndTS | ||||
| 3rdTS | ||||
| ALFS | ||||
| 12 weeks follow-up | ||||
| 24 weeks follow-up |
SHP Sanfu herbal patch, FEV1 forced expiratory volume in the first second, AQLQ Asthma Quality of Life Questionnaire, ACT Asthma Control Test, IL-5 interleukin 5, IL-13 interleukin 13, IL-23 interleukin 23, IL-25 interleukin 25, ALFS Asthma Long-term Follow-up Scale, TS treatment session